Cadila Healthcare gets EIR for its Ahmedabad SEZ plant

The receipt of EIR indicates the successful closure of the inspection points raised by the US drug regulator. The SEZ unit underwent US FDA audit from January 16 to 24, 2017.

August 29, 2017 / 12:47 IST

live

bselive
nselive

Volume

Todays L/H

Cadila Healthcare, part of Zydus Cadila on Tuesday, said it has received establishment inspection report (EIR) from US FDA for its formulation manufacturing facility at Pharma SEZ near Ahmedabad.

The receipt of EIR indicates the successful closure of the inspection points raised by the US drug regulator

The SEZ unit underwent US FDA audit from January 16 to 24, 2017.

Shares of Cadila declined 0.21 percent and were trading at Rs.500 on BSE at 12.32 pm, the benchmark Sensex dropped 0.76 and was trading 31,496.74 points.

first published: Aug 29, 2017 12:47 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347